TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Nurix Therapeutics
Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Nurix Therapeutics will host a webcast on December 8, 2025, to present new clinical data on bexobrutideg (NX-5948), an investigational BTK degrader for treating chronic lymphocytic leukemia and Waldenström macroglobulinemia.

Insights
META   negative

Mentioned in market movers with price decline (-2.67%)


NRIX   positive

Company is presenting promising clinical trial data, expanding research into targeted protein degradation medicines, and hosting an informative webcast about their drug development progress